La bourse est fermée

Pfizer Inc. (PFE)

NYSE - NYSE Prix différé. Devise en USD
Ajouter à la liste dynamique
33,17+1,08 (+3,37 %)
À la clôture : 04:02PM EDT
33,17 0,00 (0,00 %)
Échanges après Bourse : 07:59PM EDT

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323

Secteur d’activitéDrug Manufacturers—General
Employés à temps plein83 000

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Dr. Albert Bourla D.V.M., DVM, Ph.D.Chairman & CEO11,72MS.O.1962
Mr. Frank A. D'AmelioCFO & Exec. VPS.O.S.O.1958
Mr. David M. DentonChief Financial Officer & Exec. VP18,19MS.O.1965
Dr. Mikael Dolsten M.D., Ph.D.Chief Scientific Officer and Pres of R&D5,82MS.O.1958
Ms. Angela HwangChief Commercial Officer & Pres of Global Biopharmaceuticals Bus.4,89M7,7M1966
Ms. Jennifer B. DamicoSr. VP, Controller & Principal Accounting OfficerS.O.S.O.1968
Ms. Lidia L. FonsecaExec. VP and Chief Digital & Technology OfficerS.O.S.O.1969
Mr. Christopher J. Stevo CFASr. VP & Chief Investor Relations OfficerS.O.S.O.S.O.
Mr. Douglas M. LanklerExec. VP & Gen. CounselS.O.S.O.1966
Mr. Rady A. JohnsonExec. VP and Chief Compliance, Quality & Risk OfficerS.O.S.O.1962
Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.


Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Pfizer Inc. en date du 28 septembre 2023 est 5. Les scores principaux sont Audit : 10; Société : 5; Droits des actionnaires : 1; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.